Artwork

Contenuto fornito da BioTalk Unzipped. Tutti i contenuti dei podcast, inclusi episodi, grafica e descrizioni dei podcast, vengono caricati e forniti direttamente da BioTalk Unzipped o dal partner della piattaforma podcast. Se ritieni che qualcuno stia utilizzando la tua opera protetta da copyright senza la tua autorizzazione, puoi seguire la procedura descritta qui https://it.player.fm/legal.
Player FM - App Podcast
Vai offline con l'app Player FM !

Insights from AAPS PharmSci 360 Live with Dr. Mark Arnold

29:49
 
Condividi
 

Manage episode 447991301 series 3593861
Contenuto fornito da BioTalk Unzipped. Tutti i contenuti dei podcast, inclusi episodi, grafica e descrizioni dei podcast, vengono caricati e forniti direttamente da BioTalk Unzipped o dal partner della piattaforma podcast. Se ritieni che qualcuno stia utilizzando la tua opera protetta da copyright senza la tua autorizzazione, puoi seguire la procedura descritta qui https://it.player.fm/legal.

In this episode of BioTalk Unzipped, host Gregory Austin and co-host Chad Briscoe engage with Dr. Mark Arnold, a distinguished bioanalytical thought leader. They discuss the impact of recent FDA regulations on drug development, the importance of community support through the Samaritan Purse charity, especially on recent hurricane victims, and the exciting advancements in RNA editing technologies. The conversation highlights the collaborative nature of the pharmaceutical industry and the drive behind bioanalytical work, emphasizing the ultimate goal of delivering effective therapies to patients.

Chapters

00:00 Introduction to BioTalk Unzipped at AAPS PharmSci 360

03:45 Samaritan's Purse Charity and Community Impact

05:16 Most impactful talk at AAPS?

11:50 Comparative Analysis of FDA and EU Regulations

17:37 The Drive Behind Bioanalytical Work

22:24 NEW NEWS! - Innovations in RNA Editing and Bioanalysis

Takeaways

  • ​The FDA's new rules on lab-developed tests could delay biomarker utilization in clinical trials.
  • ​Community support through charities like Samaritan's Purse is crucial during crises.
  • ​The importance of collaboration in advancing drug development and bioanalytical methods.
  • ​Innovations in RNA editing present new bioanalytical challenges.
  • ​The drive to help patients is a key motivator for professionals in the field.

Sound Bites

  • ​"I worked on that drug and there's a clear benefit."
  • ​"It's getting that new therapy to a patient."
  • ​"This is going to change and potentially delay biomarkers."

New News Story:

  • ​Wave sees RNA editing validation in early trial results

https://www.biopharmadive.com/news/wave-rna-editing-aatd-first-trial-data/729981/

How to reach us:

Please donate to: Samaritan’s Purse

https://www.samaritanspurse.org/

Mark Arnold

https://www.linkedin.com/in/markearnoldphd/

Blog - https://bioanalysisandbiomarkers.blogspot.com/

Dr. Chad Briscoe

https://www.linkedin.com/in/chadbriscoe/

Celerion - https://www.celerion.com/

Gregory Austin

https://www.linkedin.com/in/gregoryaustin1/

ECI - https://eci-rx.com /

Image Credits

  • ​AAPS

  continue reading

33 episodi

Artwork
iconCondividi
 
Manage episode 447991301 series 3593861
Contenuto fornito da BioTalk Unzipped. Tutti i contenuti dei podcast, inclusi episodi, grafica e descrizioni dei podcast, vengono caricati e forniti direttamente da BioTalk Unzipped o dal partner della piattaforma podcast. Se ritieni che qualcuno stia utilizzando la tua opera protetta da copyright senza la tua autorizzazione, puoi seguire la procedura descritta qui https://it.player.fm/legal.

In this episode of BioTalk Unzipped, host Gregory Austin and co-host Chad Briscoe engage with Dr. Mark Arnold, a distinguished bioanalytical thought leader. They discuss the impact of recent FDA regulations on drug development, the importance of community support through the Samaritan Purse charity, especially on recent hurricane victims, and the exciting advancements in RNA editing technologies. The conversation highlights the collaborative nature of the pharmaceutical industry and the drive behind bioanalytical work, emphasizing the ultimate goal of delivering effective therapies to patients.

Chapters

00:00 Introduction to BioTalk Unzipped at AAPS PharmSci 360

03:45 Samaritan's Purse Charity and Community Impact

05:16 Most impactful talk at AAPS?

11:50 Comparative Analysis of FDA and EU Regulations

17:37 The Drive Behind Bioanalytical Work

22:24 NEW NEWS! - Innovations in RNA Editing and Bioanalysis

Takeaways

  • ​The FDA's new rules on lab-developed tests could delay biomarker utilization in clinical trials.
  • ​Community support through charities like Samaritan's Purse is crucial during crises.
  • ​The importance of collaboration in advancing drug development and bioanalytical methods.
  • ​Innovations in RNA editing present new bioanalytical challenges.
  • ​The drive to help patients is a key motivator for professionals in the field.

Sound Bites

  • ​"I worked on that drug and there's a clear benefit."
  • ​"It's getting that new therapy to a patient."
  • ​"This is going to change and potentially delay biomarkers."

New News Story:

  • ​Wave sees RNA editing validation in early trial results

https://www.biopharmadive.com/news/wave-rna-editing-aatd-first-trial-data/729981/

How to reach us:

Please donate to: Samaritan’s Purse

https://www.samaritanspurse.org/

Mark Arnold

https://www.linkedin.com/in/markearnoldphd/

Blog - https://bioanalysisandbiomarkers.blogspot.com/

Dr. Chad Briscoe

https://www.linkedin.com/in/chadbriscoe/

Celerion - https://www.celerion.com/

Gregory Austin

https://www.linkedin.com/in/gregoryaustin1/

ECI - https://eci-rx.com /

Image Credits

  • ​AAPS

  continue reading

33 episodi

Tutti gli episodi

×
 
Loading …

Benvenuto su Player FM!

Player FM ricerca sul web podcast di alta qualità che tu possa goderti adesso. È la migliore app di podcast e funziona su Android, iPhone e web. Registrati per sincronizzare le iscrizioni su tutti i tuoi dispositivi.

 

Guida rapida

Ascolta questo spettacolo mentre esplori
Riproduci